Neoadjuvant therapy for pancreatic cancer: an ongoing debate.

about

Improving outcomes in patients with resectable pancreatic cancer.

P2860

Q50142675-263242DD-3D10-4D19-9638-681C44AF2D60

P2860

Neoadjuvant therapy for pancreatic cancer: an ongoing debate.

Item

http://www.wikidata.org/entity/Q41826893

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Neoadjuvant therapy for pancreatic cancer: an ongoing debate.

@en

type

Item

label

Neoadjuvant therapy for pancreatic cancer: an ongoing debate.

@en

prefLabel

Neoadjuvant therapy for pancreatic cancer: an ongoing debate.

@en

P1476

Neoadjuvant therapy for pancreatic cancer: an ongoing debate.

@en

P2093

M Wasif Saif

http://www.w3.org/2001/XMLSchema#string

Suzanne Russo

http://www.w3.org/2001/XMLSchema#string

P2860

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages

DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.

A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin.

Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma.

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.

A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer.

Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer.

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.

P304

429-436

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1177/1756283X16646524

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27366211

http://www.w3.org/2001/XMLSchema#string

P932

4913343

http://www.w3.org/2001/XMLSchema#string

Neoadjuvant therapy for pancreatic cancer: an ongoing debate.

about

P2860

P2860

Neoadjuvant therapy for pancreatic cancer: an ongoing debate.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932